{HEAD ~ The method} 1, further comprising administering 1 3 additional agents selected from {TAIL ~ the group} consisting of: antihistamines, 5 lipoxygenase inhibitors, leukotriene inhibitors, H3 inhibitors, β adrenergic receptor agonists, xanthine derivatives, α adrenergic receptor agonists, mast cell stabilizers, anti tussives, expectorants, NK1, NK2 and NK3 tachykinin receptor antagonists, and GABAB agonists 
{ HEAD ~ The method } 1 , further comprising administering 1 3 additional agents selected from { TAIL ~ the group } consisting of : antihistamines , 5 lipoxygenase inhibitors , leukotriene inhibitors , H3 inhibitors , β adrenergic receptor agonists , xanthine derivatives , α adrenergic receptor agonists , mast cell stabilizers , anti tussives , expectorants , NK1 , NK2 and NK3 tachykinin receptor antagonists , and GABAB agonists
HEAD HEAD HEAD HEAD HEAD HEAD OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH TAIL TAIL TAIL TAIL TAIL TAIL OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH